📗 Cite This Artifact
Neurodegeneration Therapeutic Target Comparison Matrix
Neurodegeneration Therapeutic Target Comparison Matrix
Overview
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neurodegeneration Therapeutic Target Comparison Matrix</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">Amyloid-beta</td>
<td>[APP](/genes/app)</td>
</tr>
<tr>
<td class="label">Tau protein</td>
<td>[MAPT](/genes/mapt)</td>
</tr>
<tr>
<td class="label">Alpha-synuclein</td>
<td>[SNCA](/genes/snca)</td>
</tr>
<tr>
<td class="label">TDP-43</td>
<td>TARDBP</td>
</tr>
<tr>
<td class="label">FUS protein</td>
<td>[FUS](/genes/fus)</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">BACE1</td>
<td>[BACE1](/genes/bace1)</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>[TREM2](/genes/trem2)</td>
</tr>
<tr>
<td class="label">APOE</td>
<td>[APOE](/genes/apoe)</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>[LRRK2](/genes/lrrk2)</td>
</tr>
<tr>
<td class="label">GBA</td>
<td>GBA</td>
</tr>
<tr>
<td class="label">SNCA</td>
<td>[SNCA](/genes/snca)</td>
</tr>
<tr>
<td class="label">SOD1</td>
<td>[SOD1](/genes/sod1)</td>
</tr>
<tr>
<td class="label">C9orf72</td>
<td>[C9orf72](/genes/c9orf72)</td>
</tr>
<tr>
<td class="label">FUS</td>
<td>[FUS](/genes/fus)</td>
</tr>
<tr>
<td class="label">GRN</td>
<td>[GRN](/genes/grn)</td>
</tr>
<tr>
<td class=
Neurodegeneration Therapeutic Target Comparison Matrix
Overview
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neurodegeneration Therapeutic Target Comparison Matrix</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">Amyloid-beta</td>
<td>[APP](/genes/app)</td>
</tr>
<tr>
<td class="label">Tau protein</td>
<td>[MAPT](/genes/mapt)</td>
</tr>
<tr>
<td class="label">Alpha-synuclein</td>
<td>[SNCA](/genes/snca)</td>
</tr>
<tr>
<td class="label">TDP-43</td>
<td>TARDBP</td>
</tr>
<tr>
<td class="label">FUS protein</td>
<td>[FUS](/genes/fus)</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">BACE1</td>
<td>[BACE1](/genes/bace1)</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>[TREM2](/genes/trem2)</td>
</tr>
<tr>
<td class="label">APOE</td>
<td>[APOE](/genes/apoe)</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>[LRRK2](/genes/lrrk2)</td>
</tr>
<tr>
<td class="label">GBA</td>
<td>GBA</td>
</tr>
<tr>
<td class="label">SNCA</td>
<td>[SNCA](/genes/snca)</td>
</tr>
<tr>
<td class="label">SOD1</td>
<td>[SOD1](/genes/sod1)</td>
</tr>
<tr>
<td class="label">C9orf72</td>
<td>[C9orf72](/genes/c9orf72)</td>
</tr>
<tr>
<td class="label">FUS</td>
<td>[FUS](/genes/fus)</td>
</tr>
<tr>
<td class="label">GRN</td>
<td>[GRN](/genes/grn)</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>Aβ (protofibrils)</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>Aβ (plaques)</td>
</tr>
<tr>
<td class="label">Cinpanemab</td>
<td>α-Syn</td>
</tr>
<tr>
<td class="label">Prasinezumab</td>
<td>α-Syn</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Tau</td>
</tr>
<tr>
<td class="label">AL002</td>
<td>TREM2</td>
</tr>
<tr>
<td class="label">ASO</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Tofersen</td>
<td>[SOD1](/genes/sod1)</td>
</tr>
<tr>
<td class="label">WVE-004</td>
<td>[SOD1](/genes/sod1)</td>
</tr>
<tr>
<td class="label">BIIB080</td>
<td>[MAPT](/genes/mapt)</td>
</tr>
<tr>
<td class="label">ION363</td>
<td>[FUS](/genes/fus)</td>
</tr>
<tr>
<td class="label">ASO-C9orf72</td>
<td>[C9orf72](/genes/c9orf72)</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Target</td>
</tr>
<tr>
<td class="label">AAV-GDNF</td>
<td>GDNF</td>
</tr>
<tr>
<td class="label">AAV-BDNF</td>
<td>BDNF</td>
</tr>
<tr>
<td class="label">PBFT02</td>
<td>[GRN](/genes/grn)</td>
</tr>
<tr>
<td class="label">AVB-101</td>
<td>[GRN](/genes/grn)</td>
</tr>
<tr>
<td class="label">Zolgensma</td>
<td>SMN1</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">GLP-1 agonists</td>
<td>GLP-1R</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>mTOR</td>
</tr>
<tr>
<td class="label">Nilotinib</td>
<td>BCR-ABL/c-Abl</td>
</tr>
<tr>
<td class="label">Arimoclomol</td>
<td>HSP90</td>
</tr>
<tr>
<td class="label">Target</td>
<td>AD</td>
</tr>
<tr>
<td class="label">Aβ (APP/BACE1)</td>
<td>●●●</td>
</tr>
<tr>
<td class="label">Tau (MAPT/GSK3B)</td>
<td>●●○</td>
</tr>
<tr>
<td class="label">α-Syn (SNCA/LRRK2)</td>
<td>○</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>●●○</td>
</tr>
<tr>
<td class="label">APOE</td>
<td>●●○</td>
</tr>
<tr>
<td class="label">SOD1</td>
<td>—</td>
</tr>
<tr>
<td class="label">C9orf72</td>
<td>—</td>
</tr>
<tr>
<td class="label">FUS</td>
<td>—</td>
</tr>
<tr>
<td class="label">GRN</td>
<td>○</td>
</tr>
<tr>
<td class="label">Category</td>
<td>Phase 3</td>
</tr>
<tr>
<td class="label">Anti-amyloid</td>
<td>3</td>
</tr>
<tr>
<td class="label">Anti-tau</td>
<td>2</td>
</tr>
<tr>
<td class="label">Neuroprotection</td>
<td>4</td>
</tr>
<tr>
<td class="label">Metabolic</td>
<td>2</td>
</tr>
<tr>
<td class="label">Category</td>
<td>Phase 3</td>
</tr>
<tr>
<td class="label">Disease modification</td>
<td>2</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>1</td>
</tr>
<tr>
<td class="label">Cell therapy</td>
<td>—</td>
</tr>
<tr>
<td class="label">α-Syn targeting</td>
<td>2</td>
</tr>
<tr>
<td class="label">Category</td>
<td>Phase 3</td>
</tr>
<tr>
<td class="label">SOD1 targeting</td>
<td>1</td>
</tr>
<tr>
<td class="label">C9orf72 targeting</td>
<td>—</td>
</tr>
<tr>
<td class="label">Neuroprotection</td>
<td>3</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>—</td>
</tr>
<tr>
<td class="label">Category</td>
<td>Phase 3</td>
</tr>
<tr>
<td class="label">GRN targeting</td>
<td>—</td>
</tr>
<tr>
<td class="label">C9orf72 targeting</td>
<td>—</td>
</tr>
<tr>
<td class="label">Tau targeting</td>
<td>1</td>
</tr>
<tr>
<td class="label">TDP-43 targeting</td>
<td>—</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>AD</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>●</td>
</tr>
<tr>
<td class="label">Protein aggregation</td>
<td>●</td>
</tr>
<tr>
<td class="label">Mitochondrial dysfunction</td>
<td>●</td>
</tr>
<tr>
<td class="label">Autophagy impairment</td>
<td>●</td>
</tr>
<tr>
<td class="label">Oxidative stress</td>
<td>●</td>
</tr>
</table>
This page provides a comprehensive comparison of therapeutic targets across major neurodegenerative diseases: Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Frontotemporal Dementia (FTD). The matrix covers protein aggregation targets, genetic risk factors, and disease-modifying approaches with their clinical development status.
Therapeutic Target Comparison Matrix
Protein Aggregation Targets
Genetic Risk Factor Targets
Disease-Modifying Therapeutic Modalities
Immunotherapies
Antisense Oligonucleotides (ASOs)
Gene Therapy Approaches
Small Molecule Modulators
Target-Disease Coverage Matrix
Legend: ●●● = Primary disease target, ●●○ = Active development, ○ = Research/preclinical
Clinical Development Status Summary
Alzheimer's Disease (2026)
Parkinson's Disease (2026)
ALS (2026)
FTD (2026)
Cross-Disease Therapeutic Opportunities
Shared Mechanisms
Multi-Disease Targets in Development
Challenges and Considerations
Common Challenges
Disease-Specific Challenges
- AD: Heterogeneous pathology (Aβ, tau, inflammation)
- PD: Alpha-synuclein spread and alpha-synucleinopathy subtypes
- ALS: Rapid progression, multiple genetic causes
- FTD: Phenotypic heterogeneity, overlapping pathology
Related Pages
Therapeutic Pages
- [AD/PD Target Comparison Matrix](/therapeutics/ad-pd-target-comparison-matrix)
- [Immunotherapy Comparison](/therapeutics/immunotherapy-comparison)
- [SOD1-Targeting Therapies](/therapeutics/sod1-targeting-therapies)
- [Progranulin Therapy](/therapeutics/progranulin-therapy)
- [TREM2-Targeting Therapeutics](/therapeutics/trem2-therapeutics)
- [LRRK2 Inhibitors](/therapeutics/lrrk2-inhibitors)
- [ASO C9orf72 ALS](/therapeutics/aso-c9orf72-als)
- [FUS-ALS Treatment](/therapeutics/fus-als-treatment)
Gene/Protein Pages
- [APP Gene](/genes/app) | [APP Protein](/proteins/app)
- [BACE1 Gene](/genes/bace1) | [BACE1 Protein](/proteins/bace1)
- [MAPT Gene](/genes/mapt) | [Tau Protein](/proteins/tau)
- [GSK3B Gene](/genes/gsk3b) | [GSK3β Protein](/proteins/gsk3b)
- [SNCA Gene](/genes/snca) | [α-Synuclein](/proteins/alpha-synuclein)
- [LRRK2 Gene](/genes/lrrk2) | [LRRK2 Protein](/proteins/lrrk2)
- [TREM2 Gene](/genes/trem2) | [TREM2 Protein](/proteins/trem2)
- [APOE Gene](/genes/apoe) | [APOE Protein](/proteins/apoe)
- [SOD1 Gene](/genes/sod1) | [SOD1 Protein](/proteins/sod1)
- [C9orf72 Gene](/genes/c9orf72) | [C9orf72 Protein](/proteins/c9orf72)
- [FUS Gene](/genes/fus) | [FUS Protein](/proteins/fus)
- [GRN Gene](/genes/grn) | [Progranulin](/proteins/progranulin)
Disease Pages
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
- [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-psp)
References
Pathway Diagram
The following diagram shows the key molecular relationships involving Neurodegeneration Therapeutic Target Comparison Matrix discovered through SciDEX knowledge graph analysis:
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
- [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
- [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
Related Analyses:
- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
- [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
- [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
- [Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) 🔄
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | therapeutics-neurodegeneration-therapeutic-target-comparison-matrix |
| kg_node_id | None |
| entity_type | therapeutic |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-d27e03cd2aab |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-neurodegeneration-therapeutic-target-comparison-matrix'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-therapeutics-neurodegeneration-therapeutic-target-comparison-matrix?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Neurodegeneration Therapeutic Target Comparison Matrix](http://scidex.ai/artifact/wiki-therapeutics-neurodegeneration-therapeutic-target-comparison-matrix)
http://scidex.ai/artifact/wiki-therapeutics-neurodegeneration-therapeutic-target-comparison-matrix